Pemphigus: Study finds risk factors for relapse on rituximab

More research needed on optimal dosing schedule, investigators say

People with pemphigus with severe disease and those with persistent anti-desmoglein (DSG) antibodies three months after starting treatment with rituximab are more prone to relapse while on the drug, a study shows.